Gregory Fraser
Stock Analyst at Truist Securities
(3.26)
# 998
Out of 4,868 analysts
36
Total ratings
51.85%
Success rate
14.81%
Average return
Main Sectors:
Stocks Rated by Gregory Fraser
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANIP ANI Pharmaceuticals | Maintains: Hold | $62 → $65 | $65.51 | -0.78% | 9 | Apr 21, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $220 → $230 | $107.51 | +113.93% | 1 | Mar 6, 2025 | |
| BHC Bausch Health Companies | Maintains: Hold | $8 → $7 | $6.18 | +13.27% | 2 | Jul 25, 2024 | |
| XAIR Beyond Air | Maintains: Buy | $10 → $8 | $0.23 | +3,351.25% | 6 | Apr 30, 2024 | |
| BTMD biote | Maintains: Buy | $10 → $9 | $3.97 | +126.99% | 2 | Jan 18, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Buy | $6 → $7 | $7.82 | -10.49% | 4 | Nov 8, 2023 | |
| CORT Corcept Therapeutics | Maintains: Hold | $26 → $29 | $71.38 | -59.37% | 5 | Aug 3, 2023 | |
| NVCR NovoCure | Reiterates: Buy | $95 | $16.70 | +468.86% | 3 | Jun 6, 2023 | |
| EOLS Evolus | Maintains: Buy | $14 → $18 | $9.28 | +93.97% | 2 | May 26, 2023 | |
| ARQT Arcutis Biotherapeutics | Maintains: Buy | $45 → $40 | $13.82 | +189.44% | 2 | May 26, 2023 |
ANI Pharmaceuticals
Apr 21, 2025
Maintains: Hold
Price Target: $62 → $65
Current: $65.51
Upside: -0.78%
Jazz Pharmaceuticals
Mar 6, 2025
Maintains: Buy
Price Target: $220 → $230
Current: $107.51
Upside: +113.93%
Bausch Health Companies
Jul 25, 2024
Maintains: Hold
Price Target: $8 → $7
Current: $6.18
Upside: +13.27%
Beyond Air
Apr 30, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.23
Upside: +3,351.25%
biote
Jan 18, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $3.97
Upside: +126.99%
Amneal Pharmaceuticals
Nov 8, 2023
Maintains: Buy
Price Target: $6 → $7
Current: $7.82
Upside: -10.49%
Corcept Therapeutics
Aug 3, 2023
Maintains: Hold
Price Target: $26 → $29
Current: $71.38
Upside: -59.37%
NovoCure
Jun 6, 2023
Reiterates: Buy
Price Target: $95
Current: $16.70
Upside: +468.86%
Evolus
May 26, 2023
Maintains: Buy
Price Target: $14 → $18
Current: $9.28
Upside: +93.97%
Arcutis Biotherapeutics
May 26, 2023
Maintains: Buy
Price Target: $45 → $40
Current: $13.82
Upside: +189.44%